

Prescribing alert: NICE guidance update (to be ratified by SEL IMOC)

Type 2 diabetes in adults: management (NG28) was updated on 15/2/2022. This includes changes to prescribing guidance. The SEL Integrated Medicines Optimisation Committee (SEL IMOC) will update their T2DM guidance for SEL for the summer of 2022. HbA1c management section of the CESEL T2DM guidance (page 6) will be updated to align with SEL IMOC guidance as soon as it is available.

Type 2 Diabetes Mellitus in Adults

A guide for Lambeth General Practice

Key messages

1. Life-style changes can prevent/reduce need for medication
2. Offering education to patients at any stage is key to improving management
3. Optimise BP management adjusted for age and co-morbidities
4. Check for complications and do a QRISK
5. Optimise HbA1c adjusted for hypoglycaemic risk and frailty

Always work within your knowledge and competency

February 2022 (review June 2022, or earlier if indicated)

Why focus on Type 2 Diabetes (T2DM) in Lambeth?

Primary Care can contribute to substantially reducing diabetes complications, major vascular events and improving survival¹.

- **Covid-19:** T2DM is a risk factor for mortality with Covid-19²
- **Preventable:** Management of non-diabetic hyperglycaemia and risk factors can reduce the risk of developing T2DM³
- **Prevalent:** Diabetes is common. There are almost 19000 adults living with T2DM in Lambeth⁴
- **Under-diagnosed:** According to prevalence data, there are around 4500 adults living with undiagnosed diabetes in Lambeth (prevalence 5.6% vs 7.11% England average)⁴
- **Under-treated:** Only 34% of people with diabetes achieved the triple target* in Lambeth in 2020-21⁴

*HbA1c, BP and Cholesterol within target

Due to health inequalities, Lambeth residents are more at risk of diabetes:

Deprivation

The poorest people in the UK are **2.5 times** more likely to develop diabetes at any age³.

In Lambeth, around 30% of residents are in the lowest quintile for deprivation, and more than 70% are in the lowest 2 quintiles⁵.

Ethnicity

T2DM is up to **6 times** more common in people of South Asian descent and up to **3 times** more common among people of African-Caribbean or Black African descent³.

In Lambeth, 29.1% of residents are from ethnic minority groups⁵.


(England average 13.2%)

Risk Factors and Diagnosis

Risk factors for T2DM^{3,6}

- Age > 25 and Black African-Caribbean or Asian
 - Age > 40 and Caucasian / White European
 - Family history
 - High blood pressure
 - BMI > 25 (>23 in South Asians)
 - Waist circumference:
 - > 80cm for all women
 - > 94cm for most men
 - > 90cm for South Asian men
 - History of coronary heart disease or stroke
 - Serious mental illness
 - Polycystic ovarian syndrome and gestational diabetes
 - COVID-19 infection may precipitate a diabetes diagnosis
- Calculate T2DM risk using a [QDiabetes calculator](#)

Diagnosis using HbA1c⁷



Diagnosing diabetes using HbA1c

If initial result is within withing diagnostic range for diabetes, follow the above guidance.

Cautions regarding HbA1c:

Patients with abnormal red blood cell turnover/abnormal haemoglobin type (including haemoglobinopathy, severe anaemia, altered red cell life-span e.g. post-splenectomy, recent blood transfusion). Liaise with local lab regarding an appropriate test

Do NOT use HbA1c to diagnose in:

Type 1 diabetes, T2DM in <30 years, rapid onset of diabetes symptoms, pregnancy, up to 2 months post-partum, end-stage renal disease, acute pancreatic damage, HIV infection or if taking medication linked with hyperglycaemia, e.g. long-term corticosteroids

Principles of care

	Non-diabetic Hyperglycaemia (NDH)	New diagnosis of Diabetes
Support patient understanding	Support patients/carers to reach an understanding of the diagnosis and implications and what they can do to care for themselves Use Diabetes UK Information Prescriptions to support personal care (can be downloaded into EMIS)	
Code correctly	Use Ardens pre-diabetes clinical template	Use Ardens diabetes clinical template
Structured education	Emphasise to patients and carers that structured education is integral to their care.	
	Refer to Healthier You NHS Diabetes Prevention Programme (DXS) if criteria met	Refer / encourage self refer to Diabetes Book and Learn
Follow-up	Offer annual review to patients with NDH/or history of gestational diabetes: HbA1c + Vital 5 : BP, BMI, smoking status, mental health and alcohol intake	Agree clear date for next review All patients should in addition have annual review with NICE eight care processes (8CPs) (see page 4) plus annual retinal screening

Considering pregnancy⁸

1. Start folic acid 5mg daily, 3 months before conceiving
2. Check medications for contraindications (see page 5,6)
3. Check HbA1C, renal function, TFT
4. Refer Diabetes Pre-conception clinic at KCH or GSTT (via ERS)
5. As soon a pregnancy confirmed inform Diabetes pregnancy clinic kch-trdiabetesnurses@nhs.net or gst-tr.diabetesandendocrine@nhs.net

WORRYING SYMPTOMS

New T2DM, >60 years, weight loss - 2WW referral for suspected cancer of pancreas⁹

HbA1c >85mmol/mol +/- weight loss at diagnosis: consider Type 1, ketosis prone, latent autoimmune diabetes in adults (LADA). Seek specialist advice.

T2DM Eight Care Processes (8CP)¹⁰

1

Body Mass Index kg/m^{11,12}

Page 5

Overweight: BMI ≥ 25 Caucasian / White European groups, BMI ≥ 23 Black African, African Caribbean and Asian groups
Agree an initial weight loss target of 5–10% of body weight

Undertake all care processes at least annually. Individualise all targets, review dates and monitoring

2

Blood Pressure^{11,13}

Page 5

QOF ≤140/80mmHg excludes those with moderate or severe frailty
NICE ≤140/90mmHg if under 80 years; ≤ 150/90mmHg if ≥ 80 years; ≤130/80 mmHg if CKD

3

Cholesterol¹⁴

Page 6

Primary prevention: Offer statin if QRISK >10% after addressing modifiable risk factors
Secondary prevention (history of CVD): Offer high dose statin aiming for 40% reduction in non-HDL level

QOF target excludes those with moderate or severe frailty
Women of child-bearing age need contraception during statin treatment and for 1 month afterwards. Discontinue statins 3 months before trying to conceive

4

HbA1c^{14,15}

Page 6

It takes 3 months from medication dose change to see HbA1c change. Check 3 monthly until target is reached then every 6 months
Target: **≤48mmol/mol** (6.5%) unless taking a drug that could cause adverse low sugars/hypos e.g. gliclazide, insulin
≤53mmol/mol (7%) if on a drug that **could** cause low sugars/hypos
≤75 mmol/mol (9%) if moderate/severe frailty (QOF)

Individualise HbA1c target especially for those with reduced life expectancy, risk of falls and/or significant co-morbidities

5

Smoking

ASK ADVISE ACT Ensure you are trained to deliver Very Brief Advice (VBA) [Very Brief Advice Training Module](#)
If ready to quit refer to [Lambeth Specialist Stop Smoking service](#)

6

Renal function and albumin creatinine ratio (ACR)^{17,18}

Measure serum creatinine **and** urine ACR; consider CKD if low eGFR* (<60ml/min/1.73m²) and/or raised ACR (≥ 3 mg/mmol)
Use the [One London Diabetic Kidney Disease Risk Stratification](#) to identify those at high risk of diabetic kidney disease progression for patients with eGFR<45ml/min/ 1.73m²
Ideally early morning urine, if random sample then confirm any ACR between 3-70 mg/mmol with an early morning sample. If ACR ≥70 mg/mmol, repeat not needed
Nephropathy – start an ACEI/ARB even if normotensive

*it is no longer recommended to correct eGFR for ethnicity

8

Foot Check¹⁹

Medium risk (neuropathy/absent pulse)
refer to Community Podiatry Clinic via DXS

High risk – neuropathy/absent pulse + plus deformity or skin changes in previous ulcer - Urgently refer to Community Podiatry Clinic via DXS

Active ulcer / infection / ischaemia
Urgent KCH/GSTT foot clinic or A&E out of hours

Resource for clinicians: [Annual foot review pathway](#), [Diabetes UK](#)

Resource for patients: [Diabetes and Looking After Your Feet](#)

+

Vital 5

Includes mental health + alcohol intake

Retinopathy screening within 3 months of diagnosis and at least annually¹⁴

Should be called automatically once T2DM coded, check happening at annual review

Vaccination

Flu annually and pneumococcal once³

BP and Weight Management

Identify and address all modifiable risk factors

Individualise targets and goals, especially for those with moderate or severe frailty

Check understanding and adherence and set a review date

Blood pressure^{11,13,15}

Diagnosis

Diagnosis	See CESEL Lambeth Hypertension guide Confirm diagnosis with ABPM or HBPM
Measuring BP in T2DM	<ul style="list-style-type: none"> Measure sitting & standing BP in T2DM If postural drop (≥ 20mmHg SBP) review medications and treat to target on standing BP

Which BP target?

NICE	Age <80 yrs $\leq 140/90$ mmHg Age ≥ 80 yrs $\leq 150/90$ mmHg CKD if ACR ≥ 70 mg/mmol $\leq 130/80$
QOF¹⁵	$\leq 140/80$ mmHg (excludes those with moderate or severe frailty)

Weight Management^{12,15}

Physical Activity

For All	Increased physical activity, even without weight loss, brings health benefits
To prevent obesity	40-60 mins moderate intensity exercise / day
With a history of obesity	60-90 mins moderate intensity exercise/day to avoid weight gain

Step 1*

ACEI or ARB**

ramipril/lisinopril or losartan

Drugs to avoid at conception/in pregnancy include:

ACEI/ARB/thiazide or thiazide-like diuretic (increased risk of congenital abnormalities).

NICE guidelines: Stop ACEI/ARB and change medication within 2 working days of notification of pregnancy. Offer alternatives:

Labetalol if no CI (eg asthma), nifedipine or methyldopa.

Can also remain on amlodipine – GSTT Obstetric Medicine advice

Target BP $\leq 135/85$ mmHg

Highlight all co-morbidities on antenatal booking form (even if already self-referred) to ensure triage into appropriate clinic and contact diabetes pregnancy team (see p3)

Step 2*

ACEI or ARB** + CCB or thiazide-like diuretic

ramipril/lisinopril or losartan

amlodipine or indapamide (IR)

Step 3*

ACEI or ARB** + CCB + thiazide-like diuretic

If uncontrolled on optimal doses regard as **resistant hypertension**
Repeat ABPM/HBPM, assess for postural hypotension, discuss adherence

Step 4*

Consider further diuretic with **low-dose spironolactone** if potassium ≤ 4.5 mmol/L and good renal function. If potassium >4.5 mmol/L and/or reduced renal function prescribe **alpha-blocker** (doxazosin) or **beta-blocker** (atenolol/bisoprolol) and/or consider seeking specialist advice

*Optimise medication to most effective tolerated dose and check adherence at each step, before stepping up

**For people of Black African or African-Caribbean origin, use ARB instead of ACEI as increased risk of angioedema with ACEI

Weight management referral

- General advice on healthy weight and lifestyle to all
- Tailor interventions to patients' circumstances and choices
- Signpost to local and national resources (see page 11)

BMI ≥ 30 with co-morbidity or BMI ≥ 27 for BAME adults

Offer referral: **Tier 2**

- Lambeth Early Intervention Prevention Service **LEIPS**
- NHS Digital Weight Management** supports adults living with obesity who also have a diagnosis of diabetes, hypertension or both, to manage their weight via 12 week online programme

BMI ≥ 35

Offer referral: **Tier 3**

- SEL **Tier 3** Healthy Weight programme
- ERS referral using form on DXS
- Include BP, BMI, HbA1c, lipid profile and creatinine

BMI ≥ 35 + Would consider bariatric surgery + Tier 3 completed

Offer referral: **Tier 4**

- Bariatric Service (KCH or GSTT) via ERS
- Include details of Tier 3 programme for eligibility

HbA1c and Lipid Management

Identify and address all modifiable risk factors

Individualise targets and goals, especially for those with moderate or severe frailty

Check understanding and adherence and set a review date

Prescribing alert: NICE guidance update

Type 2 diabetes in adults: management (NG28) was updated on 15/2/2022. This includes changes to prescribing guidance. The **SEL Integrated Medicines Optimisation Committee (SEL IMOC)** will update their T2DM guidance for SEL for the summer of 2022. This section of the CESEL T2DM guidance will be updated to align with SEL IMOC guidance as soon as it is available.

HbA1c Management^{11,14,15}

Step 1
3 months

Person-centred lifestyle advice

If HbA1c \geq 48mmol/mol (6.5%)* go to Step 2

*Individualise targets and goals

For patients with moderate or severe frailty the QOF target is \leq 75 mmol/mol (9%)

Step 2
3 m from dose change

Metformin standard release

- Start 500mg daily with/after food and increase by 500mg every 2 weeks until on 1g twice a day (MR if GI side effects)
- Aim for HbA1c of \leq 48mmol/mol (6.5%)*
- If HbA1c \geq 58mmol/mol (7.5%)* go to step 3

Step 3
3 m from dose change

Gliclazide preferred 2nd line for most patients¹⁶ (guidance under review)

- Consider alternative to gliclazide (Gliptins, SGLT-2 and Pioglitazone) especially if BMI \geq 35, frail elderly or concern regarding hypoglycaemia e.g. Group 2 driver
- Gliclazide dose 40mg-80mg once to twice daily with meals
- Titrate on pre-meal blood glucose target 4-6mmol/mol, individualised BM target or HbA1c
- If HbA1c \geq 58mmol/mol (7.5%)* go to step 4

Step 4
3 m from dose change

Third agent needed, or considering insulin, or contra-indication to metformin/gliclazide?

Refer to [South East London Blood Glucose Control Management Pathway for Adults with Type 2 Diabetes Mellitus](#)

Guidance aligns with SEL IMOC Blood Glucose Control Management Pathway for Adults with Type 2 Diabetes

Need more help?

Refer to [Lambeth Diabetes Intermediate Care team](#) via ERS, using form on DXS or email lamccg.diabetes@nhs.net or Advice and Guidance (ERS)

Community Hypertension and Lipid Clinic: DXS referral or advice

See [SEL Lipid Management 2021](#) for criteria

Lipid Management^{10,14}

Cardiovascular risk

Management of cardiovascular risk factors is essential to prevent and reduce macrovascular complications of diabetes

- Perform baseline bloods (non-fasting lipid profile, LFT, TFT, HbA1c, renal profile)
- Record weight, smoking status, BP
- Calculate QRISK except in CKD/albuminuria or familial hypercholesterolaemia
- Offer education and lifestyle interventions to modify CVD risk
- Use shared decision-making to consider risk vs benefit of drug therapy

Primary Prevention

If QRISK \geq 10% start **Atorvastatin 20mg OD** (or Rosuvastatin 10mg OD) after addressing modifiable risk factors*

- Calculate baseline non-HDL level (total cholesterol minus HDL cholesterol)
- Repeat lipids after 3 months aiming for **40% reduction in non-HDL level**

\geq 40% reduction | Review annually

< 40% reduction | 1. Consider up-titration of statin to max dose **Atorvastatin 80mg** (or Rosuvastatin 20mg)
2. If intolerant to higher dose consider adding ezetimibe 10mg daily. If intolerant to statins start ezetimibe and refer to lipid clinic.

If still not achieving target after further 3 months refer to lipid clinic

*caution in pregnancy

Secondary Prevention

History of CVD (MI, angina, stroke/TIA, peripheral vascular disease, abdominal aortic aneurysm)

Offer high dose, high intensity statin: **Atorvastatin 40-80mg OD or max tolerated dose** (or Rosuvastatin 20mg OD)

- Calculate baseline non-HDL level (total cholesterol minus HDL cholesterol)
- Repeat lipids after 3 months aiming for **40% reduction in non-HDL level**

\geq 40% reduction | Review annually

< 40% reduction | Ensure on max tolerated dose of statin and consider adding **Ezetimibe 10mg**

If still not achieving target after further 3 months refer to lipid clinic

(If no baseline value: consider a target non-HDL cholesterol < 2.5mmol/L or LDL cholesterol < 2mmol/L)

Guidance aligns with SEL IMOC Lipid Management: Medicines Optimisation Pathways

Type 2 Diabetes review (at least annual)

Principles of remote monitoring: [LTC during COVID-19 guide \(page 4\)](#)

	Tasks/Activity	Who?	Where?	Tools/Support
Review planning at practice level	Call/recall planning: Use searches to help determine who to invite for review first, focusing on the triple target and the 8CP	Admin colleague with clinician support (pharmacist/nurse/GP)	In practice or remotely via EMIS	EMIS searches e.g. EZ Analytics and Ardens searches
Pre-patient review	Contact patient to: <ol style="list-style-type: none"> 1. Arrange bloods (renal function, FBC, lipids, HbA1c) & urine ACR 2. Arrange BP measurement (in practice/<u>machine at home</u>), at least annually 3. Height and weight: home measurements for remote reviews 	HCA/ Nurse	In practice/at home/ at pharmacy	Use E-consult “diabetes review” or AccuRx for pre-review information-gathering. Text/ contact patient to encourage to complete ahead of review <u>BP@Home</u> if available
Patient review	<ol style="list-style-type: none"> 1. Review patient concerns 2. Review BMI, BP trend and Pulse check 3. Review investigations: HbA1c, Cholesterol, renal function, urine ACR 4. Re-calculate QRISK (if appropriate) 5. Discuss risk-reduction + life-style: in context of QRISK, <u>Vital 5</u> (BMI, smoking, alcohol, diet, activity) & COVID 6. Medication review: any concerns with a focus on side-effects and adherence. Signpost to community pharmacy for <u>New Medicines Service</u>. Ensure renal function, HbA1c, cholesterol and BP satisfactory and titrate or initiate medications if needed. 7. Mind + Body: consider <u>screening for mental health conditions</u>. 8. Foot check examination and advice on foot care - share link via Accurx <u>Diabetes UK advice on Footcare</u> 9. Eye check: Check patient is receiving annual eye check ups 10. Driving: Use Driver and Vehicle Licensing Agency (DVLA)’s <u>Assessing fitness to drive: a guide for medical professionals</u> to guide into account self-monitoring of blood glucose levels for adults with type 2 diabetes. 	Pharmacist/ Nurse/ GP	Remote or F2F	EMIS templates e.g. Ardens Diabetes template (for correct coding, annual review, medication review & Vital 5 recording) <u>Diabetes Book and Learn</u> for structured education <u>Brief-interventions</u> around lifestyle
	<ol style="list-style-type: none"> 11. Goal setting/Self-management/Shared decision-making 	Pharmacist/ Nurse/ GP or Social prescriber, Care Navigator & Patient		Self-management resources, see page 11- send links via AccuRx. <u>Diabetes UK Information Prescriptions to support personal care</u>
Follow-up	Review as agreed, e.g. monthly until BP at target, 3 monthly until HbA1C at target	GP/ Pharmacist/ Nurse/HCA		

QRISK

QRISK3 is preferred as QRISK2 can underestimate cardiovascular risk. Currently there is a link to QRISK3 in the Ardens templates. If this is unavailable use QRISK2 calculator in EMIS

QRISK is not applicable in people considered at high risk of CVD (Type 1 DM, CKD3-5), existing CVD, stroke/ TIA, as they should already be on lipid modification. It is also not applicable in people >85years

Type 2 Diabetes review (continued)

Further considerations:																										
Dietary advice Diabetes UK	<ul style="list-style-type: none"> • Eat plenty of vegetables • Have sufficient fibre in your diet • Eat fish, especially oily fish (mackerel, salmon, sardines) regularly • Cut down on: <ul style="list-style-type: none"> • sugary food and drinks • energy dense foods such as crisps, cakes, biscuits and pastries • alcohol • salty, processed foods 	Consider doing the CDEP Nutrition learning module to increase your knowledge of diet and T2DM																								
Goal setting	Support your patients to make SMART goals e.g. Specific: 'I want to lose weight' Measurable: 'I'll aim to lose 2kg' Achievable: 'I attend a Book and Learn course to help me' Realistic: 'I'll ask my family to help too' Timed: 'I will do this over the next 6 months'	Watch this short patient video on achieving goals Involve Health and Wellbeing Coach																								
Personalised care	'A one-size-fits-all health and care system simply cannot meet the increasing complexity of people's needs and expectations. Personalised care is based on 'what matters' to people and their individual strengths and needs.' NHS England	Consider learning through the Personalised Care Institute , or encouraging patients to work with a Social Prescribing Link Worker (SPLW) to help take control																								
Sick day rules²⁰	<ul style="list-style-type: none"> • If available increase glucose monitoring to at least 4 times a day when unwell • Maintain fluid and carbohydrate intake. Sugary fluids if glucose low and sugar-free fluids if glucose high • NEVER stop insulin: change dose of insulin and gliclazide according to glucose readings <p>Patients should seek medical advice if they:</p> <ul style="list-style-type: none"> • have no access to glucose monitoring and experience symptoms of high glucose – e.g. thirst, polyuria, fatigue • are unable to maintain hydration or take carbohydrates due to vomiting • have persistently high or low glucose despite altering medication doses • other concerns <p>If changing medication doses remember to change them back when better i.e. eating and drinking normally for 2 days</p>	<table border="1" style="width: 100%; border-collapse: collapse; background-color: #f2f2f2;"> <thead> <tr> <th colspan="4" style="text-align: center; padding: 5px;">SADMANS rules</th> </tr> <tr> <th colspan="4" style="text-align: center; padding: 5px;">Consider stopping these classes of drugs temporarily during dehydrating illness</th> </tr> </thead> <tbody> <tr> <td style="text-align: center; padding: 5px;">S</td> <td style="padding: 5px;">SGLT-2 inhibitors</td> <td style="text-align: center; padding: 5px;">M</td> <td style="padding: 5px;">Metformin</td> </tr> <tr> <td style="text-align: center; padding: 5px;">A</td> <td style="padding: 5px;">ACE inhibitors</td> <td style="text-align: center; padding: 5px;">A</td> <td style="padding: 5px;">ARBs</td> </tr> <tr> <td style="text-align: center; padding: 5px;">D</td> <td style="padding: 5px;">Diuretics</td> <td style="text-align: center; padding: 5px;">N</td> <td style="padding: 5px;">NSAIDs</td> </tr> <tr> <td></td> <td></td> <td style="text-align: center; padding: 5px;">S</td> <td style="padding: 5px;">Sulfonylureas</td> </tr> </tbody> </table> <p style="margin-top: 10px;">Links to send via accuRx:</p> <ol style="list-style-type: none"> 1. What to do when you are ill 2. Sick day rules 3. NHS Video library guide to using glucometer 	SADMANS rules				Consider stopping these classes of drugs temporarily during dehydrating illness				S	SGLT-2 inhibitors	M	Metformin	A	ACE inhibitors	A	ARBs	D	Diuretics	N	NSAIDs			S	Sulfonylureas
SADMANS rules																										
Consider stopping these classes of drugs temporarily during dehydrating illness																										
S	SGLT-2 inhibitors	M	Metformin																							
A	ACE inhibitors	A	ARBs																							
D	Diuretics	N	NSAIDs																							
		S	Sulfonylureas																							

Prescribing alert: NICE guidance update

Type 2 diabetes in adults: management (NG28) was updated on 15/2/2022). This includes changes to prescribing guidance. The SEL Integrated Medicines Optimisation Committee (SEL IMOC) will update their T2DM guidance for SEL for the summer of 2022. This section of the CESEL T2DM guidance will be updated to align with SEL IMOC guidance as soon as it is available.

	Drug	Starting dose	Daily Range	Notes (these are not extensive, please refer to the latest BNF for further information especially titration increments/cautions/contra-indications)
Biguanide	Metformin	500mg OD	Metformin standard release Start 500mg daily with/after food and increase by 500mg every 2 weeks until on 1g BD or maximum tolerated dose	<ul style="list-style-type: none"> • Ensure eGFR >45ml/min, or review dose. Contraindicated if eGFR <30ml/min*. Routine renal function at least annually, 6 monthly for those at risk of renal impairment. • Consider slow-release preparation if standard preparation causes gastrointestinal side effects. • Take with meals to reduce gastrointestinal side effects • Remember sick day rules ▀ p.8 • Manufacturer advises patients and carers should be informed to seek urgent medical advice if symptoms of lactic acidosis e.g. dyspnoea, cramps, abdominal pain
Sulfonylureas	Gliclazide	40mg – 80mg daily	160mg-320 mg daily, doses over 160mg divided. Titrate every 2 weeks according to pre-meal blood glucose – 4-6mmol/L or individualised target or against 3 monthly HbA1c.	<ul style="list-style-type: none"> • Inform patients of risk of adverse events/hypoglycaemia, particularly if renal impairment • Advise patients on how to manage hypoglycaemia • Use with care in those with mild to moderate renal impairment (eGFR 30-60ml/min), only prescribe under specialist advice in severe impairment (eGFR <30ml/min) • Self monitor according to DVLA guidance and consider alternative if Group 2 driver (large lorries and buses) • Consider alternative if BMI >35 • Care with frail elderly, housebound and certain occupations e.g., working heavy machinery
ACEI	1st line Ramipril	2.5mg OD (1.25mg OD in frail/elderly patients)	2.5mg-10mg OD	<ul style="list-style-type: none"> • For people of Black African or African-Caribbean family origin, use ARB instead of ACEI (as increased risk of angioedema with ACEI) • Check base line U&Es and renal profile (Na/K/Cr/eGFR). Hyperkalaemia may occur, therefore close monitoring of serum potassium is required • Re-check renal profile within 2 weeks of initiation or dose increase and then at least annually. • Titrate ACEI/ARB up at 2-4 weekly intervals to achieve optimal BP control • Initiation/dose titration: if Cr increases by >20% (or eGFR falls by >15%) stop ACEI and seek specialist advice. ACEI dose should only be increased if serum creatinine increases by <20% (or eGFR falls by <15%) after each dose titration and potassium <5.5mmol • ACEI/ARB dose should be optimised before the addition of a second agent • Side effects: symptomatic hypotension can occur on first dosing – suggest take at night. Dry cough with ACEI, consider switch to ARB • Caution: Do not combine ACEI and ARB to treat hypertension • For diabetic nephropathy ARB of choice: losartan and irbesartan
	2nd line Lisinopril	10mg OD	10-80mg OD (maintenance dose 20mg for hypertension)	
ARBs	Losartan	50mg OD (25mg OD if >75yrs old)	50-100mg OD	<ul style="list-style-type: none"> • Side effects: symptomatic hypotension can occur on first dosing – suggest take at night. Dry cough with ACEI, consider switch to ARB • Caution: Do not combine ACEI and ARB to treat hypertension • For diabetic nephropathy ARB of choice: losartan and irbesartan
	Candesartan	8mg OD	8mg-32mg OD	

*Latest NICE CKD guidance (August 2021) does **not** recommend adjusting the estimation of glomerular filtration rate (GFR) in people of African-Caribbean or African family background

Prescribing alert: NICE guidance update

Type 2 diabetes in adults: management (NG28) was updated on 15/2/2022. This includes changes to prescribing guidance. The [SEL Integrated Medicines Optimisation Committee](#) (SEL IMOC) will update their T2DM guidance for SEL for the summer of 2022. This section of the CESEL T2DM guidance will be updated to align with SEL IMOC guidance as soon as it is available.

	Drug	Starting dose	Daily Range	Notes (these are not extensive, please refer to the latest BNF for further information especially titration increments/cautions/contra-indications)
CCBs	Amlodipine	5mg OD	5-10mg OD	<ul style="list-style-type: none"> Increase after 2-4 weeks to maximum dose of 10mg OD. Caution: Interacts with simvastatin – consider switching to atorvastatin. If amlodipine causes ankle oedema consider using a thiazide-like diuretic instead CI: unstable angina, aortic stenosis, severe hypotension Side effects include flushing and headaches at initiation; swollen ankles especially at higher doses
Thiazide-like diuretics	Indapamide (IR)	2.5mg OD	2.5mg OD	<ul style="list-style-type: none"> Check baseline renal profile, then after 2 weeks, then at least annually. If K < 3.5mmol/L or eGFR <25ml/min, stop indapamide and seek specialist advice.
Aldosterone receptor antagonist (K ⁺ sparing diuretic)	Spironolactone	25mg OD	25mg OD	<ul style="list-style-type: none"> Step 4: Spironolactone is the preferred diuretic at step 4 (NICE), but is an unlicensed indication in resistant hypertension (BNF) Consider only if potassium ≤4.5mmol/L (caution in reduced eGFR <30ml/min, as increased risk of hyperkalaemia). Monitor Na/K/renal function within 1 month and repeat 6 monthly thereafter If K>4.5mmol/L should be stopped.
α-B	Doxazosin (IR)	1mg OD	2-16mg OD (or BD dosing when >8mg/day)	<ul style="list-style-type: none"> Consider at Step 4 if potassium ≥ 4.5mmol/L. Initial dose of 1mg usually increased after 1-2 weeks to 2mg OD At doses above 8mg/day, consider split dosing from OD to BD to reduce BP variation Caution: Initial dose as may cause postural hypotension, avoid in elderly as orthostatic hypotension risk
β-B	Atenolol	25mg OD	25-50mg OD	<ul style="list-style-type: none"> Consider at Step 4 if potassium ≥ 4.5mmol/L. Particular caution in T2DM – symptoms of hypoglycaemia may be masked. Beta blockers may be considered in younger people and in those with an intolerance/CI to ACEI/ARBs, women of childbearing potential, co-existent anxiety/tachycardia/heart failure. CI: asthma, 2nd/3rd degree AV block, severe PAD Caution: beta blockers can cause bradycardia if combined with certain CCBs e.g. Verapamil/Diltiazem
	Bisoprolol	5-10mg OD	5-20mg OD	
Statin (See page 6)	Atorvastatin (alternative is rosuvastatin)	20mg OD	20-80mg OD	<ul style="list-style-type: none"> Seek specialist advice if eGFR <30ml/min, liver disease, untreated hypothyroidism, heavy drinker CI in pregnancy, breast feeding, avoid or address contraceptive needs women of childbearing age. Advise to stop 3 months before conception. Multiple drug interactions, check BNF for advice, avoid grapefruit juice Advise patient to visit GP if they experience unexplained muscle pains Refer to SEL IMOC Guidelines on Lipid Management

Resources:

Patient resources

- Patients with pre-diabetes can [self-register](#) with the NHS Diabetes Prevention Programme
- [NHS Digital Weight Management Programme](#) a 12 week online behavioural and lifestyle programme
- [Lambeth GP Food Co-op](#) build food growing gardens in NHS surgeries & patients participate in food growing groups
- [Diabetes Book and Learn](#): NHS south London Diabetes Education Booking Service.
- [The Diabetes UK Lambeth and Southwark Group](#): support and information for everyone with diabetes and their carers.
- Diabetes UK: [Patient information leaflets in different languages](#)
- Lambeth health and wellbeing [information and support](#) (smoking, healthy eating and physical activity)
- NHS Better Health [free tools and support](#) to kickstart your health (weight, smoking, activity, alcohol)
- Physical activity for older people with [Silverfit](#)
- Local activity finders: [getactive](#) and [gomammoth](#)
- Walking for health: [Lambeth Community Health Walking Scheme](#)
- Lowering your blood pressure with [DASH diet](#)
- Diabetes UK [Diabetes and looking after your feet](#)
- Discounted prices at Lambeth Leisure Centres [REAL Plus Leisure Card](#)

Lambeth Clinical Support

Urgent telephone advice- Consultant connect: Diabetes at GSTT/KCH by telephone or via App

Virtual diabetes clinics- These are available for practices via Lambeth DICT (see below)

[Lambeth Diabetes Intermediate Care team \(DICT\)](#)

Referral criteria on form (see DXS). Can also contact via email: lamccg.diabetes@nhs.net

Specialist clinics- Request **advice and guidance** or referral to specialist clinics via eRS to: Diabetes medicine (GSTT/KCH), Pre-conception counselling clinic (GSTT/KCH), Diabetes Pregnancy clinic (GSTT /KCH), CKD clinic (GSTT/KCH)]

Professional resources

Healthier You NHS Diabetes Prevention, see referral pathway via DXS

- [Cambridge Diabetes Education Programme](#), comprehensive, competence based learning. Free for all Lambeth clinicians REGISTRATION KEY CODE: **DIABETESLAMBETH**
- [Diabetes in Healthcare](#) Diabetes UK free on line learning for health professionals
- [RCGP Diabetes Hub](#)
- [Personalised Care Institute](#)
- [Primary Care Diabetes Society](#)
- [RCGP Quality Improvement Toolkit for Diabetes Care](#)
- Annual [foot review](#) Diabetes UK

Acknowledgements

CESEL guides are co-developed by SEL primary care clinicians and SEL experts and are localised to include borough specific pathways and resources. The guides go through a formal approval process including SEL Integrated Medicines Optimisation Committee (IMOC) for the medicines content, a local borough-based Primary Care Leads group and CESEL Steering Group with representation from SELCCG and PCNs, and borough-based Medicines Teams.

CESEL would like to thank all our colleagues who participated and fed-back during the consultation process, in particular the Lambeth Federation, the Lambeth Clinical Cabinet, Lambeth Together, Lambeth Medicines Optimisation team, Lambeth DICT and colleagues from SELIMOC. Public Health and King's Health Partners

References:

1. [The Cost of Diabetes Report. Diabetes UK 2014](#) [accessed Feb 2022]
2. [Barron E et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. The Lancet Diabetes and Endocrinology. 8\(10\) P813-822, 2020](#) [accessed Feb 2022]
3. [Diabetes UK](#)
4. [QOF data, 2020-21](#)
5. [Lambeth Health Profile 2017](#) [accessed Feb 2022]
6. [The Global Registry of New-Onset, COVID-19-Related Diabetes](#) [accessed Feb 2022]
7. [Consensus Approach to the Diagnosis of Type 2 Diabetes. London Diabetes Clinical Network September 2018](#) [accessed Feb 2022]
8. [Diabetes in pregnancy: management from preconception to the postnatal period. NICE \(NG3\) Feb 2015, update Dec 2020](#) [accessed Feb 2022]
9. [Suspected cancer: recognition and referral NICE \(NG12\) June 2015](#) [accessed Feb 2022]
10. [National Diabetes Audit – Care Processes and Treatment Targets: 2019-20](#) [accessed Feb 2022]
11. [Quality and Outcomes Framework guidance for 2021/22:BMA&NHS](#) [accessed Feb 2022]
12. [Obesity: identification, assessment and management. NICE guideline \(CG189\) Nov 2014](#) [accessed Feb 2022]
13. [Hypertension in adults: diagnosis and management. NICE guideline \(CG136\) Aug 2019](#) [accessed Feb 2022]
14. [SE London Integrated Medicines Optimisation Committee \(SEL IMOC\):Lipid management: Medicines Optimisation Pathways](#) [accessed Feb 2022]
15. [Type 2 Diabetes in adults: Management. NICE Guideline \(NG28\) Dec 2015, updated Dec 2020](#) [accessed Feb 2022]
16. [South East London Blood Glucose Control Management Pathway for Adults with Type 2 Diabetes Mellitus October 2019](#) [accessed Feb 2022]
17. [Chronic kidney disease in adults: assessment and management. NICE guideline \(NG203\) August 2021](#) [accessed Feb 2022]
18. [OneLondon Diabetic Kidney Disease Risk Stratification Pathway Winter 2020/21](#)
19. [Diabetic foot problems: prevention and management NICE guideline \(NG19\) August 2015, updated January 2016](#) [accessed Feb 2022]
20. [London Clinical Network Guidance Sick day rules: how to manage Type 2 diabetes if you become unwell with coronavirus and what to do with your medication](#) Updated April 2020 [accessed Feb 2022]
21. [British National Formulary, last updated Dec 2021](#)

Abbreviations:

2WW – Two week wait referral	IGR – Impaired Glucose Regulation
α-B – Alpha blocker	IR – Immediate release
A&E – Accident and Emergency	K – Potassium
ABPM – Ambulatory blood pressure monitoring	KCH – King’s College Hospital
ACEI– Angiotensin converting enzyme inhibitor	HbA1c – Haemoglobin A1c %
ACR – Albumin-creatinine ratio	HBPM– Home blood pressure monitoring
ALT – Alanine aminotransferase	HDL – High-density lipoprotein
APL – Active Patient Link tools	IGR – Impaired glucose regulation
ARB – Angiotensin receptor blocker	IHD – Ischaemic Heart Disease
AST – Aspartate aminotransferase	IR – Immediate release
BAME – Black, Asian and Minority Ethnic	LFT – Liver function tests
β-B – Beta blocker	LADA – Latent autoimmune diabetes in adults
BD – Twice daily (dosing)	LDL – Low-density lipoprotein
BM- Blood monitoring	MI – Myocardial infarction
BMI – Body mass index	NDA – National Diabetes Audit
BNF – British National Formulary	NICE – The National Institute for Health and Care Excellence
BP – Blood Pressure	NSAID – Non steroidal anti-inflammatory
CDEP – Cambridge diabetes Education Programme	OD – Once daily (dosing)
CES – Clinical Effectiveness Southwark	PAD – Peripheral Arterial Disease
CCB – Calcium channel blocker	PCOS – Polycystic Ovarian Syndrome
CI – contra-indication	PHM – Population health management (contract)
CK – Creatinine Kinase	PLT – Protected Learning Time
CKD – Chronic Kidney Disease	PMS – Primary medical services (contract)
Cr – Creatinine	QOF – Quality and outcomes framework (contract)
CVD – Cardiovascular disease	QRISK2 – a prediction algorithm for CVD. EMIS currently using QRISK2 (although QRISK3 released in 2017)
DASH – Dietary approaches to stop hypertension	RCGP – Royal College of General Practitioners
DESMOND – Diabetes Education and Self-Management for Ongoing and Diagnosed	Renal profile – this includes serum sodium/potassium/creatinine/eGFR
DPP – Diabetes Prevention Programme	SELAPC – South East London Area Prescribing Committee
DVLA – Driver and Vehicle Licensing Agency	SEL – South East London
DXS – Point-of-care tool for EMIS Web	SBP – Systolic blood pressure
ECG – Electrocardiogram	SGLT-2 inhibitor – Sodium-glucose Cotransporter-2 inhibitor
eGFR – Estimated glomerular filtration rate	SPC – Summary of product characteristics
ERS – Electronic Referral System	SPLW – Social Prescribing Link Worker
F2F – Face to face	T2DM – Type 2 Diabetes Mellitus
FBC – Full blood count	TIA – Transient ischaemic attack
GSTT – Guy’s and St. Thomas’ Hospital	TFT – Thyroid function blood tests
GI – Gastro-intestinal	

Making the right thing to do
the easy thing to do.